Buccafusco Jerry J, Webster Scott J, Terry Alvin V, Kille Nancy, Blessing Donna
Alzheimer's Research Center, Medical College of Georgia, Augusta, GA 30912-2300, USA.
Psychopharmacology (Berl). 2009 Jan;202(1-3):477-85. doi: 10.1007/s00213-008-1318-1. Epub 2008 Sep 11.
The alpha(2)-adrenergic receptor agonist clonidine was examined for its ability to improve working memory in monkeys.
Clonidine (0.116-34.8 microg/kg) was administered to six pigtail macaques in their performance of a computer-assisted delayed matching-to-sample (DMTS) task.
During DMTS sessions initiated 1 hour after dosing, there was a slight improvement in mean task accuracy (long delay trials; 0.116-microg/kg). On the following day, there was continued and added improvement in accuracies associated with the long delay trials. On the day following 1.16-microg/kg, the entire memory retention curve was shifted to the right of vehicle. When the animals were again tested 48 hours after dosing (no pretreatment), these two patterns of task enhancement were continued and enhanced. Mean task accuracy associated with long delay trials was significantly increased by 14.2% trials correct when animals were originally treated with 0.116-microg/kg of clonidine. Mean task accuracy associated with medium delay trials was significantly increased by 11.8% trials correct when animals were treated with 1.16-microg/kg. On the sixth day after clonidine, task accuracies were still significantly improved during medium delay trials after 0.116-microg/kg. Median sample and choice latencies were not significantly influenced by clonidine treatment. These findings are consistent with the ability of clonidine to induce a protracted improvement in aspects of working memory.
Early (attentional) and late (retention) components of memory appeared to be differentially sensitive to the dose of clonidine. Central alpha(2)-adrenergic receptors should be considered legitimate drug targets for future compound development for cognition enhancement.
研究了α₂-肾上腺素能受体激动剂可乐定改善猴子工作记忆的能力。
给6只猪尾猕猴注射可乐定(0.116 - 34.8微克/千克),同时让它们执行计算机辅助延迟匹配样本(DMTS)任务。
给药后1小时开始的DMTS实验过程中,平均任务准确率有轻微提高(长延迟实验;0.116微克/千克)。在接下来的一天,长延迟实验的准确率持续提高且有所增加。在注射1.16微克/千克后的第二天,整个记忆保持曲线向右移动至溶剂对照组右侧。给药48小时后(未进行预处理)再次对动物进行测试时,这两种任务增强模式持续且增强。最初用0.116微克/千克可乐定治疗的动物,与长延迟实验相关的平均任务准确率显著提高,正确实验次数增加了14.2%。用1.16微克/千克治疗的动物,与中延迟实验相关的平均任务准确率显著提高,正确实验次数增加了11.8%。可乐定给药后的第六天,0.116微克/千克剂量下,中延迟实验期间任务准确率仍显著提高。样本和选择潜伏期的中位数未受可乐定治疗的显著影响。这些发现与可乐定诱导工作记忆方面长期改善的能力一致。
记忆的早期(注意力)和晚期(保持)成分似乎对可乐定剂量的敏感性不同。中枢α₂-肾上腺素能受体应被视为未来开发用于增强认知的化合物的合理药物靶点。